MAX - SHOCK Clinical Trial

Launched by OTTAWA HEART INSTITUTE RESEARCH CORPORATION · Aug 14, 2024

Keywords

ClinConnect Summary

The MAX - SHOCK Clinical Trial is exploring a way to improve a treatment called Electrical Cardioversion (ECV) for patients with a heart condition known as atrial fibrillation (AF). ECV is a procedure that helps restore a normal heart rhythm, and this trial is specifically looking at whether using a more powerful device can lead to better results. Researchers will compare two devices: one that delivers a maximum energy of 360 joules and another that delivers 200 joules. They believe that the stronger device may help more patients successfully return to a normal heart rhythm.

To participate in this trial, individuals must be over 18 years old, have persistent atrial fibrillation, and be scheduled for ECV at the University of Ottawa Heart Institute (UOHI). It's important to note that certain conditions, like having a blood clot in the heart or being part of another clinical trial, would prevent someone from participating. Once enrolled, participants can expect to receive either the higher or lower energy treatment during their scheduled procedure, helping researchers learn which option works better for restoring heart rhythm.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients age \> 18 years.
• • Persistent atrial fibrillation.
• • Scheduled for elective cardioversion at UOHI
• • Patient is within the circle of care of UOHI Electrophysiology staff
• Exclusion Criteria:
• • Known left-atrial appendage thrombus.
• • Contraindication to appropriate anticoagulation.
• • Patient is included in another randomized clinical trial.
• • Patient does not meet all of the above listed inclusion criteria.